What is Klotho Neurosciences, Inc.'s earnings per share (EPS)?

Klotho Neurosciences, Inc. (KLTOW) reported diluted earnings per share of $-0.32 for fiscal year 2024. This represents a -540.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Klotho Neurosciences, Inc. Financials

KLTOW

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Klotho Neurosciences, Inc. (KLTOW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Klotho Neurosciences, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.48x

For every $1 of reported earnings, Klotho Neurosciences, Inc. generates $0.48 in operating cash flow (-$2.9M OCF vs -$6.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-55.4x

Klotho Neurosciences, Inc. earns $-55.4 in operating income for every $1 of interest expense (-$5.5M vs $100K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$6.2M

YoY-769.4%

Klotho Neurosciences, Inc. reported -$6.2M in net income in fiscal year 2024. This represents a decrease of 769.4% from the prior year.

EPS (Diluted)

$-0.32

YoY-540.0%

Klotho Neurosciences, Inc. earned $-0.32 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 540.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$64K

YoY+2170.0%

Klotho Neurosciences, Inc. held $64K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

21M

YoY+141.6%

Klotho Neurosciences, Inc. had 21M shares outstanding in fiscal year 2024. This represents an increase of 141.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-518.9%

YoY-395.1pp

Klotho Neurosciences, Inc.'s ROE was -518.9% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 395.1 percentage points from the prior year.

Capital Allocation

R&D Spending

Klotho Neurosciences, Inc. invested $0 in research and development in fiscal year 2024.

Share Buybacks

N/A

Capital Expenditures

N/A

KLTOW Income Statement

Metric	FY24	FY23	FY22
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$0	$0	N/A
SG&A Expenses	$129K+323.7%	$31K-94.3%	$534K
Operating Income	-$5.5M-777.6%	-$631K+3.9%	-$657K
Interest Expense	$100K+31.2%	$76K	N/A
Income Tax	N/A	$691K+114.4%	$322K
Net Income	-$6.2M-769.4%	-$707K-157.4%	$1.2M
EPS (Diluted)	$-0.32-540.0%	$-0.05	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$271K+13.6%	$239K	$0	N/A	$0	$0	$0	N/A
SG&A Expenses	$231K-31.8%	$339K-4.3%	$355K	N/A	$52K+2127.8%	$2K-74.5%	$9K	N/A
Operating Income	-$1.9M+2.1%	-$1.9M-19.3%	-$1.6M	N/A	-$2.9M-625.7%	-$396K+41.1%	-$672K	N/A
Interest Expense	$1.2M-33.1%	$1.8M+217.7%	$554K	N/A	$45K+198.4%	$15K	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$49K	N/A
Net Income	-$2.9M+29.3%	-$4.1M-83.2%	-$2.2M	N/A	-$3.0M-555.3%	-$452K+32.8%	-$672K-431.4%	-$126K
EPS (Diluted)	$-0.05+58.3%	$-0.12-50.0%	$-0.08	N/A	$-0.18	$-0.03+25.0%	$-0.04	N/A

KLTOW Balance Sheet

Metric	FY24	FY23	FY22
Total Assets	$2.5M+12.1%	$2.2M-98.1%	$118.2M
Current Assets	$158K+2273.8%	$7K-98.5%	$440K
Cash & Equivalents	$64K+2170.0%	$3K-99.2%	$341K
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$1.3M-21.5%	$1.6M-98.7%	$122.3M
Current Liabilities	$1.2M-23.0%	$1.6M+220.2%	$506K
Long-Term Debt	N/A	N/A	N/A
Total Equity	$1.2M+107.3%	$572K+114.1%	-$4.0M
Retained Earnings	-$10.6M-169.2%	-$3.9M+3.0%	-$4.0M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$10.1M-7.1%	$10.8M+263.1%	$3.0M+21.6%	$2.5M-0.3%	$2.5M-25.5%	$3.3M-83.1%	$19.6M+793.2%	$2.2M
Current Assets	$7.8M-9.0%	$8.5M+1142.7%	$688K+335.8%	$158K+2.0%	$155K-84.5%	$1000K+12318.8%	$8K+21.1%	$7K
Cash & Equivalents	$7.3M-13.4%	$8.4M+1389.9%	$566K+787.8%	$64K+25.2%	$51K-94.0%	$845K+10399.8%	$8K+186.7%	$3K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$146K-25.3%	$195K-91.7%	$2.3M+84.6%	$1.3M+26.7%	$1.0M-79.4%	$4.9M-74.7%	$19.2M+1086.1%	$1.6M
Current Liabilities	$93K+47.5%	$63K-97.3%	$2.3M+87.4%	$1.2M+27.0%	$982K+9.3%	$899K-65.2%	$2.6M+59.4%	$1.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.9M-6.8%	$10.7M+1567.5%	$639K-46.1%	$1.2M-18.8%	$1.5M+194.1%	-$1.6M-530.9%	$360K-37.0%	$572K
Retained Earnings	-$19.8M-17.1%	-$16.9M-32.0%	-$12.8M-21.1%	-$10.6M-24.3%	-$8.5M-53.5%	-$5.5M+28.4%	-$7.7M-97.0%	-$3.9M

KLTOW Cash Flow Statement

Metric	FY24	FY23	FY22
Operating Cash Flow	-$2.9M-559.3%	-$447K+9.4%	-$493K
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	-$123K-617.8%	$24K+100.0%	-$116.2M
Financing Cash Flow	$3.1M+794.6%	$350K-99.7%	$117.0M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$1.1M+44.7%	-$2.0M-26.7%	-$1.6M-64.6%	-$944K+12.0%	-$1.1M-18.2%	-$907K-4029.2%	-$22K+89.0%	-$200K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	$0	$0+100.0%	-$1+100.0%	-$123K-223.3%	$100K
Financing Cash Flow	$5K-99.9%	$9.8M+378.3%	$2.1M+114.8%	$957K+243.6%	$279K-83.8%	$1.7M+883.1%	$175K+75.0%	$100K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KLTOW Financial Ratios

Metric	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	-518.9%-395.1pp	-123.7%	N/A
Return on Assets	-250.3%-218.0pp	-32.3%-33.3pp	1.0%
Current Ratio	0.13+0.1	0.00-0.9	0.87
Debt-to-Equity	1.07-1.8	2.83+33.1	-30.24
FCF Margin	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-29.2%+9.3pp	-38.4%+311.3pp	-349.8%	N/A	-202.6%	N/A	-186.7%-164.5pp	-22.1%
Return on Assets	-28.7%+9.0pp	-37.7%+37.0pp	-74.8%	N/A	-120.1%-106.5pp	-13.7%-10.2pp	-3.4%+2.3pp	-5.8%
Current Ratio	83.69-52.1	135.74+135.4	0.29+0.2	0.13-0.0	0.16-1.0	1.11+1.1	0.000.0	0.00
Debt-to-Equity	0.010.0	0.02-3.7	3.68+2.6	1.07+0.4	0.69+3.8	-3.13-56.5	53.40+50.6	2.83
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.13), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

Is Klotho Neurosciences, Inc. profitable?

No, Klotho Neurosciences, Inc. (KLTOW) reported a net income of -$6.2M in fiscal year 2024.

What is Klotho Neurosciences, Inc.'s return on equity (ROE)?

Klotho Neurosciences, Inc. (KLTOW) has a return on equity of -518.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Klotho Neurosciences, Inc.'s operating cash flow?

Klotho Neurosciences, Inc. (KLTOW) generated -$2.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Klotho Neurosciences, Inc.'s total assets?

Klotho Neurosciences, Inc. (KLTOW) had $2.5M in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Klotho Neurosciences, Inc. have outstanding?

Klotho Neurosciences, Inc. (KLTOW) had 21M shares outstanding as of fiscal year 2024.

What is Klotho Neurosciences, Inc.'s current ratio?

Klotho Neurosciences, Inc. (KLTOW) had a current ratio of 0.13 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Klotho Neurosciences, Inc.'s debt-to-equity ratio?

Klotho Neurosciences, Inc. (KLTOW) had a debt-to-equity ratio of 1.07 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Klotho Neurosciences, Inc.'s return on assets (ROA)?

Klotho Neurosciences, Inc. (KLTOW) had a return on assets of -250.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Klotho Neurosciences, Inc.'s cash runway?

Based on fiscal year 2024 data, Klotho Neurosciences, Inc. (KLTOW) had $64K in cash against an annual operating cash burn of $2.9M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Klotho Neurosciences, Inc.'s Piotroski F-Score?

Klotho Neurosciences, Inc. (KLTOW) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Klotho Neurosciences, Inc.'s earnings high quality?

Klotho Neurosciences, Inc. (KLTOW) has an earnings quality ratio of 0.48x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Klotho Neurosciences, Inc. cover its interest payments?

Klotho Neurosciences, Inc. (KLTOW) has an interest coverage ratio of -55.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.